BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 65%* for Big Cap Pro

1 year 40%, 2 years 50% and *3 years 65%

*Across 3 years $2276.64 only $796.82

ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,969.34
      0.35%
      US Tech 100
      20,353.20
      0.60%
      Dow Jones
      44,296.51
      0.97%
      Brent Oil
      74.595
      -0.23%
      Bitcoin
      98,227.93
      0.19%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. RAPT Therapeutics Inc (RAPT) Quote

      RAPT Therapeutics Inc

      RAPT Therapeutics Inc (RAPT)

      NASDAQ
      1.08
      0.03
      (2.86%)
      Closed November 22 4:00PM
      Delayed by 15 minutes
      1.08
      0.00
      ( 0.00% )
      Pre Market: 5:18AM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      1.08
      Bid
      1.07
      Ask
      1.25
      Volume
      7,835
      0.00 Day's Range 0.00
      1.00 52 Week Range 27.35
      Market Cap
      37.755M
      Previous Close
      1.08
      Open
      -
      Last Trade
      3000
      @
      1.08
      (formt)
      Last Trade Time
      05:27:00
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      541,298
      Shares Outstanding
      34,958,253
      Dividend Yield
      -
      PE Ratio
      -0.32
      Earnings Per Share (EPS)
      -3.34
      Revenue
      -
      Net Profit
      -116.8M

      About RAPT Therapeutics Inc

      RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX... RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.rapt.com
      Headquarters
      Dover, Delaware, USA
      Founded
      -
      RAPT Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RAPT. The last closing price for RAPT Therapeutics was $1.08. Over the last year, RAPT Therapeutics shares have traded in a share price range of $ 1.00 to $ 27.35.

      RAPT Therapeutics currently has 34,958,253 shares outstanding. The market capitalization of RAPT Therapeutics is $37.75 million. RAPT Therapeutics has a price to earnings ratio (PE ratio) of -0.32.

      Ask ADVFN Intelligence (AI)

      RAPT Latest News

      More News

      Form 8-K - Current report

      November 15 2024
      Edgar (US Regulatory)

      Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

      November 14 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      November 12 2024
      Edgar (US Regulatory)

      RAPT Therapeutics Reports Third Quarter 2024 Financial Results

      SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing...

      November 12 2024
      GlobeNewswire Inc.

      Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury

      SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering...

      November 11 2024
      GlobeNewswire Inc.

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      August 08 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      August 08 2024
      Edgar (US Regulatory)

      RAPT Therapeutics Reports Second Quarter 2024 Financial Results

      SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing...

      August 08 2024
      GlobeNewswire Inc.

      Form 8-K - Current report

      July 19 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      May 23 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.11-9.243697478991.191.2217109421.07838151CS
      4-0.8-42.55319148941.883.32111211071.74605536CS
      12-1-48.07692307692.083.3215412981.7924967CS
      26-3.14-74.40758293844.224.614573872.4245912CS
      52-12.69-92.156862745113.7727.3517269068.17008425CS
      156-30.98-96.63131628232.0640.74147716914.52793737CS
      260-20.12-94.905660377421.251.2095140257519.15026459CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      WLDSWearable Devices Ltd
      $ 3.26
      (73.40%)
      		1.38M
      QMMMQMMM Holdings Limited
      $ 1.24
      (65.36%)
      		12.73M
      CMAXCareMax Inc
      $ 1.11
      (54.17%)
      		115.84k
      ANLAdlai Nortye Ltd
      $ 3.90
      (48.29%)
      		7
      RGTIRigetti Computing Inc
      $ 2.55
      (46.55%)
      		26.68M
      ONCTOncternal Therapeutics Inc
      $ 0.72
      (-36.84%)
      		20.01k
      AKTSAkoustis Technologies Inc
      $ 0.0691
      (-31.31%)
      		4.77M
      HSTMHealthStream Inc
      $ 25.12
      (-21.96%)
      		6
      ACTUActuate Therapeutics Inc
      $ 7.11
      (-20.82%)
      		1
      SRDXSurModics Inc
      $ 31.27
      (-20.49%)
      		1
      RGTIRigetti Computing Inc
      $ 2.55
      (46.55%)
      		26.68M
      QMMMQMMM Holdings Limited
      $ 1.24
      (65.36%)
      		12.73M
      ELABElevai Labs Inc
      $ 0.0172
      (-14.43%)
      		9.61M
      AKTSAkoustis Technologies Inc
      $ 0.0691
      (-31.31%)
      		4.77M
      QUBTQuantum Computing Inc
      $ 7.01
      (14.92%)
      		4.03M

      RAPT Discussion

      View Posts
      Monksdream Monksdream 3 months ago
      RAPT under $3
      👍️0
      Monksdream Monksdream 3 months ago
      RAPT new 52 week low
      👍️0
      Monksdream Monksdream 3 months ago
      RAPT new 52 low
      👍️0
      Monksdream Monksdream 4 months ago
      RAPT under $4
      👍️0
      Monksdream Monksdream 7 months ago
      RAPT new 52 week
      👍️0
      Monksdream Monksdream 7 months ago
      RAPT under $10
      👍️0
      tickersym tickersym 9 months ago
      Bargin prices!! Lets go!!
      👍️0
      Stockexpertpro Stockexpertpro 9 months ago
      RAPT Only 1 Patient had a problem out of 350 people enrolled in the trial

      https://finance.yahoo.com/news/1-fda-puts-hold-two-125809258.html Fire sale down here lots of upgrades out last weeK
      👍️0
      StockLogistics StockLogistics 2 years ago
      Surprised that no gap fill occurred prior to results expected near September 12, showing major strength buoyed by estimates of 50.00:

      “8:04a ET 5/23/2022 - Benzinga
      RAPT Therapeutics Announces Initiation Of Phase 2b Trial Of RPT193 In Patients With Moderate-to-Severe Atopic Dermatitis

      RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it has initiated its 16-week randomized, double-blind, placebo-controlled Phase 2b clinical trial to further evaluate the efficacy and safety of RPT193 as monotherapy in patients with moderate-to-severe atopic dermatitis (AD).”
      👍️0
      StockLogistics StockLogistics 2 years ago
      12.16 gap fill over the next 14.5 weeks
      👍️0
      StockLogistics StockLogistics 2 years ago
      12.16 gap fill over the next 14.5 weeks
      👍️0
      StockLogistics StockLogistics 2 years ago
      15 weeks to go

      8:04a ET 5/23/2022 - Benzinga
      RAPT Therapeutics Announces Initiation Of Phase 2b Trial Of RPT193 In Patients With Moderate-to-Severe Atopic Dermatitis

      Countdown to potential billions in revenue.
      👍️0
      StockLogistics StockLogistics 2 years ago
      A ton of insider buying last week
      👍️0
      StockLogistics StockLogistics 2 years ago
      Positive sentiment about billions that could be made from Rapt’s drug and pipe financing, perfect storm brewing
      👍️0
      Glider549 Glider549 3 years ago
      It happens,,and more often than not doesn't.
      That's why I'd trim, but leave some on the table.
      👍️0
      weasel4339 weasel4339 3 years ago
      It's way up after hours bud
      👍️0
      Glider549 Glider549 3 years ago
      Can't believe some of you did not take profits near the close.
      Greed will kill ya.
      👍️0
      pennyfinder pennyfinder 3 years ago
      Will do
      👍️0
      weasel4339 weasel4339 3 years ago
      I'll keep n eye out. Let me knoe if u hear something about the price
      👍️0
      pennyfinder pennyfinder 3 years ago
      Supposed to be. There’s no price set on the offering. They just said they’re raising $125M, they could be raising at $50… who knows… but the history has always been lower than the closing price. We will have to wait and see.
      👍️0
      weasel4339 weasel4339 3 years ago
      This considered dilution?
      👍️0
      pennyfinder pennyfinder 3 years ago
      LOL

      https://investors.rapt.com/news-releases/news-release-details/rapt-therapeutics-announces-proposed-public-offering-common
      👍️0
      make it happen make it happen 3 years ago
      Most def. Idk how these companies even give a PT like that. Happens way to often and retails get blindsided. I wouldn't even do that if had all the power too.
      👍️0
      pennyfinder pennyfinder 3 years ago
      Offering AH or tomorrow pre
      👍️0
      make it happen make it happen 3 years ago
      Negative 1,000% plus operating margins. Only Phase 1 still, A long way to go...

      Large negative lose percentages across the board on margins.

      Only $0.22 revenue per share

      Cash flow will burn all money before end of year.

      Profitability
      Profit Margin 0.00%
      Operating Margin (ttm) -1,064.70%

      Management Effectiveness
      Return on Assets (ttm) -27.62%
      Return on Equity (ttm) -50.34%

      Income Statement
      Revenue (ttm) 5.33M
      Revenue Per Share (ttm) 0.22
      Quarterly Revenue Growth (yoy) 30.70%
      Gross Profit (ttm) 5.04M
      EBITDA -55.53M
      Net Income Avi to Common (ttm) -56.27M
      Diluted EPS (ttm) -2.29

      Balance Sheet
      Total Cash (mrq) 98.41M
      Total Cash Per Share (mrq) 3.93
      Total Debt (mrq) N/A
      Total Debt/Equity (mrq) N/A
      Current Ratio (mrq) 9.21
      Book Value Per Share (mrq) 3.69

      Cash Flow Statement
      Operating Cash Flow (ttm) -45.66M
      Levered Free Cash Flow (ttm) -23.3M
      👍️0
      StockLogistics StockLogistics 3 years ago
      This stock reported legitimate results of its study and is a short squeeze candidate imo if Reddit wanted to wake up to it
      👍️0
      Roadtojourney Roadtojourney 5 years ago
      Not even 6 months old and already offering??
      👍️0
      crudeoil24 crudeoil24 5 years ago
      RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It is developing selective small molecules designed to modulate the critical immune responses underlying these diseases. It has discovered and advanced two drug candidates FLX475 and RPT193, which is engaged in targeting C-C motif chemokine receptor 4 (CCR4). Its drug discovery and development engine has identified CCR4 as a drug target that potentially has broad applicability in oncology and inflammatory diseases. Its lead oncology drug candidate FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory Treg cells into tumors. Its RPT193 drug candidate, is designed to selectively inhibit the migration of type 2 T helper cells (Th2 cells), into allergically-inflamed tissues.
      👍️0
      crudeoil24 crudeoil24 5 years ago
      42.00 > hod.

      RAPT
      👍️0
      crudeoil24 crudeoil24 5 years ago
      29.01 x 30.00

      RAPT
      👍️0
      crudeoil24 crudeoil24 5 years ago
      Multiple Nasdaq circuit breakers halts today

      RAPT
      👍️0
      crudeoil24 crudeoil24 5 years ago
      7.7M shares trading float >

      RAPT
      👍️0

      Your Recent History

      NASDAQ
      RAPT
      RAPT Therapeutics
      Delayed Upgrade Clock